ZA201007649B - 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c - Google Patents

7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Info

Publication number
ZA201007649B
ZA201007649B ZA2010/07649A ZA201007649A ZA201007649B ZA 201007649 B ZA201007649 B ZA 201007649B ZA 2010/07649 A ZA2010/07649 A ZA 2010/07649A ZA 201007649 A ZA201007649 A ZA 201007649A ZA 201007649 B ZA201007649 B ZA 201007649B
Authority
ZA
South Africa
Prior art keywords
indolo
benzazepine
hepatitis
treatment
carboxylic acid
Prior art date
Application number
ZA2010/07649A
Other languages
English (en)
Inventor
Scott W Martin
Carl P Bergstrom
Min Ding
Xiaofan Zheng
Robert G Gentles
Original Assignee
Bristol-Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201007649(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Co filed Critical Bristol-Myers Squibb Co
Publication of ZA201007649B publication Critical patent/ZA201007649B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2010/07649A 2008-05-06 2010-10-26 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c ZA201007649B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06
PCT/US2009/042805 WO2009137454A1 (en) 2008-05-06 2009-05-05 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
ZA201007649B true ZA201007649B (en) 2012-04-25

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07649A ZA201007649B (en) 2008-05-06 2010-10-26 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Country Status (19)

Country Link
US (1) US8133884B2 (enExample)
EP (1) EP2280975B1 (enExample)
JP (1) JP2011520810A (enExample)
KR (1) KR20110015588A (enExample)
CN (1) CN102083834A (enExample)
AR (1) AR071684A1 (enExample)
AU (1) AU2009244409A1 (enExample)
BR (1) BRPI0915130A2 (enExample)
CA (1) CA2723683A1 (enExample)
CL (1) CL2009001089A1 (enExample)
CO (1) CO6290645A2 (enExample)
EA (1) EA201001748A1 (enExample)
IL (1) IL208753A0 (enExample)
MX (1) MX2010011921A (enExample)
NZ (1) NZ588556A (enExample)
PE (1) PE20091879A1 (enExample)
TW (1) TW200951135A (enExample)
WO (1) WO2009137454A1 (enExample)
ZA (1) ZA201007649B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US8431568B2 (en) 2008-03-27 2013-04-30 Bristol-Myers Squibb Company Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
BR112015000714A2 (pt) * 2012-07-18 2017-06-27 Bristol Myers Squibb Holdings Ireland processos e intermediários para a preparação de (4bs,5ar)-12-ciclo-hexil-n-(n,n-dimetilsulfamoil)-3-metóxi-5a-((1r,5s)-3-metil-3,8-diazabiciclo[3.2.1]octano-8-carbonil)-4b,5,5a, 6-tetra-hidrobenzo [3,4]ciclopropa[5,6]azepino[1,2-a] indol-9-carboxamida

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Also Published As

Publication number Publication date
AU2009244409A1 (en) 2009-11-12
IL208753A0 (en) 2010-12-30
CO6290645A2 (es) 2011-06-20
EP2280975B1 (en) 2014-01-01
CA2723683A1 (en) 2009-11-12
PE20091879A1 (es) 2009-12-19
CL2009001089A1 (es) 2011-04-29
WO2009137454A1 (en) 2009-11-12
EP2280975A1 (en) 2011-02-09
BRPI0915130A2 (pt) 2019-09-24
JP2011520810A (ja) 2011-07-21
CN102083834A (zh) 2011-06-01
NZ588556A (en) 2012-06-29
AR071684A1 (es) 2010-07-07
US8133884B2 (en) 2012-03-13
EA201001748A1 (ru) 2011-06-30
KR20110015588A (ko) 2011-02-16
MX2010011921A (es) 2010-11-30
TW200951135A (en) 2009-12-16
US20090280083A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
ZA201101739B (en) Compounds for the treatment of hepatitis c
ZA201007526B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
ZA201007983B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
DK3872059T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
PL2297073T3 (pl) Sposób wytwarzania 2, 3, 3, 3-trifluoropropenu
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
ZA200906129B (en) Compounds for the treatment of hepatitis c
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
EP2225002A4 (en) RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
IL219914A0 (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
PL2225238T3 (pl) Pochodne amidów kwasu 6,7-dihydro-5H-imidazo[1,2-a]imidazolo-3-karboksylowego
PL2209784T3 (pl) Związki do leczenia zapalenia wątroby typu C
ZA201000923B (en) Compounds for the treatment of hepatitis c
IL207520A0 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
PL2137206T3 (pl) Sposób wytwarzania kwasu tauroursodeoksycholowego
ZA201007649B (en) 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
SI2225232T1 (sl) Postopek za pripravo substituiranih 1,3-oksatiolanov
EP2157089A4 (en) THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES
EP1996192A4 (en) PROCESS FOR PREPARING 3,4-SUBSTITUTED THIAZOLIDIN-2-ONES IN 3,4
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
ZA201003264B (en) Method for the preparation of 2 chloro1,1,1,2,3,3,3 heptafluopropane
GB201114785D0 (en) 2-Fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivatives, process for the preparation of sam, and process for the preparation of monofluoromethyl-coating